Drug Resistance, Neoplasm

"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Descriptor ID	D019008
MeSH Number(s)	G07.690.773.984.395
Concept/Terms	Drug Resistance, Neoplasm Drug Resistance, Neoplasm Resistance, Antineoplastic Agent Resistance, Antineoplastic Drug Drug Resistance, Antineoplastic Neoplasm Drug Resistance Antineoplastic Agent Resistance Antineoplastic Drug Resistance Antibiotic Resistance, Neoplasm Antibiotic Resistance, Neoplasm

Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Drug Resistance [G07.690.773.984]
Drug Resistance, Neoplasm [G07.690.773.984.395]

Below are MeSH descriptors whose meaning is related to "Drug Resistance, Neoplasm".

Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.

Bar chart showing 163 publications over 24 distinct years, with a maximum of 14 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2002	1	0	1
2003	2	2	4
2004	1	2	3
2005	0	3	3
2007	3	1	4
2008	1	3	4
2009	0	6	6
2010	3	8	11
2011	2	6	8
2012	0	2	2
2013	5	6	11
2014	8	3	11
2015	6	4	10
2016	8	6	14
2017	5	3	8
2018	6	7	13
2019	4	6	10
2020	1	6	7
2021	4	9	13
2022	0	1	1
2023	1	4	5
2024	2	5	7
2025	1	5	6

Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.

Peng M, Lee S, Nair HG, MacGilvary N, Cong K, Kraemer M, Li R, McConnell J, Baer C, Deng B, Zhu L, Cantor SB. RAD51 is chromatin enriched and targetable in BRCA1-deficient cells. Mol Cell. 2025 Sep 18; 85(18):3373-3387.e6.

View in: PubMed
Xue T, Liu X, Song C, Fei S, Gu J, Han Y, Xing J, Liu X, Liang F, Thompson PR, Zhang X. Citrullination of AKT2 Catalyzed by PAD1 Facilitates the Maintenance of Stemness Characteristics of Ovarian Cancer Stem-Like Cells in Ovarian Cancer. Adv Sci (Weinh). 2025 Oct; 12(39):e01014.

View in: PubMed
Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, Sato T, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.

View in: PubMed
Herzog TJ, Liao JB, Finkelstein K, Willmott L, Duan W, Moroney JW, Buscema J, Campbell-Simms K, Yue Y, Zweizig S, Liu J, Wang X, Zang RY, Yin R, O'Malley DM, Wu L. An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.

View in: PubMed
Vincoff S, Goel S, Kholina K, Pulugurta R, Vure P, Chatterjee P. FusOn-pLM: a fusion oncoprotein-specific language model via adjusted rate masking. Nat Commun. 2025 Feb 07; 16(1):1436.

View in: PubMed
Whalen JM, Earley J, Silva C, Mercurio AM, Cantor SB. Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability. Nat Cancer. 2025 Feb; 6(2):278-291.

View in: PubMed
Voorhees P, Suman V, Efebera Y, Raje N, Tuchman S, Rodriguez C, Laubach J, Bova-Solem M, Carlisle D, Usmani S, McCarthy P, Richardson PG. Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse. Blood Adv. 2024 10 08; 8(19):5039-5050.

View in: PubMed
Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E, Huo S, Zhang Y, Qureshi ZP, Jagannath S. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Front Immunol. 2024; 15:1408892.

View in: PubMed
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah U, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Usmani SZ, Chung DJ. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood. 2024 07 25; 144(4):402-407.

View in: PubMed
Yaniv B, Tanenbaum B, Kazakova V, Patel SA. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma. Leuk Res. 2024 Jul; 142:107519.

View in: PubMed

People

Explore

Similar Concepts

Top Journals